R&D update: Mammalian Display service
09 February 2023
New commerical service from
OptiMAL® programme
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and
diagnostic applications, announces that is has launched a new commercial
service from its R&D programme, named Mammalian Display, for high
volume mammalian cell surface expression and screening of antibodies.
Mammalian Display is the first service from the Company’s ongoing
OptiMAL® programme which Fusion has commercialised and is now offering
to clients. The service is particularly suited to companies specialising
in the identification of therapeutic antibodies from focussed libraries
of sequences, such as would be required by those entities using
artificial intelligence (“AI”) or machine learning (“ML”)
which can require the expression and screening of small libraries of
tens of thousands of antibodies.
Fusion collaborates with its clients in every stage of pre-clinical
antibody development, with decades of experience and unique proprietary
platforms. A fully integrated end-to-end service from therapeutic target
nomination and discovery through to stable cell line development in
readiness for GMP production is also available. Initial market research
that the Company has conducted with AI/ML experts has confirmed that
there is a need for expression of focussed libraries of antibodies in
the way delivered by the Mammalian Display service.
The Company is continuing to work on other aspects of the OptiMAL®
programme, and in particular the development of the fully human antibody
library.
Fusion Antibodies CEO, Adrian Kinkaid said: “We are delighted to be able to announce the successful development of the Mammalian Display technology, an output from our OptiMAL® research programme. As our industry rapidly turns to find new ways to hasten the development of better bio-therapeutics to the clinic, we also anticipate deploying these capabilities to bring AI generated antibody sequences out of world class computer algorithms and into a world class antibody laboratory.”
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Adrian Kinkaid, Chief Executive Officer James Fair, Chief Financial Officer |
Via Walbrook PR | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
| James Reeve/Vivek Bhardwaj (Corporate
Finance) Tony Quirke (Sales and Corporate Broking) |
||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the development
of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
generation, development, production, characterisation and optimisation.
These services include antigen expression, antibody production,
purification and sequencing, antibody humanisation using Fusion's
proprietary CDRx TM platform and the
production of antibody generating stable cell lines to provide material
for use in clinical trials. Since 2012, the Company has
successfully sequenced and expressed over 250 antibodies and
successfully completed over 200 humanisation projects and has an
international, blue-chip client base, which has included eight of the
top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and
diagnostic companies to develop innovative products in a timely and
cost-effective manner for the benefit of the global healthcare industry.
Fusion Antibodies provides a broad range of services in antibody
generation, development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new
platforms that will enable Pharma and Biotech companies get to the
clinic faster, with the optimal drug candidate and ultimately speed up
the drug development process.
The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.
